Webinar The Real Challenges of Global Clinical Research
watching
WEBINARThe Real Challenges of Global Clinical Research
WEBINAR

The Real Challenges of Global Clinical Research

A practical lens for spotting the operational, regulatory, and human failure points that derail global studies, and planning around them

April 22, 2026
1 / 39
WEBINARThe Real Challenges of Global Clinical Research

This webinar follows the full global execution path

  1. 1
    Global ambition creates local friction in predictable places
  2. 2
    Regulatory paths diverge and reshape startup critical paths
  3. 3
    Protocol complexity amplifies burden across countries and sites
  4. 4
    Recruitment, site load, data quality, and a risk-first playbook
2 / 39
WEBINARThe Real Challenges of Global Clinical Research

Global studies are chosen for good reasons, but the usual story is incomplete

Sponsors go global to reach patients faster, diversify populations, satisfy market expectations, and support label strategy. Those are real advantages, but they often overshadow the operational fact that every added country is a new system, not just a new site list.

  • More countries can widen access to patients, not guarantee speed
  • Population diversity can strengthen evidence, if execution is stable
  • Market goals often shape footprint before operations are tested
  • The planning error is treating expansion as a scaling problem only
3 / 39
WEBINARThe Real Challenges of Global Clinical Research

Complexity shows up first in ordinary work, not in dramatic failures

Global execution rarely breaks because of one spectacular event. It usually slows through dozens of small mismatches in document requirements, visit logistics, training, language, lab handling, and payment flow, each too minor to trigger alarm until timelines slip.

  • Submission packs vary in content, sequence, and local formatting
  • Sites absorb translation, workflow, and staffing friction unevenly
  • Patients feel burden through travel, time, and trust gaps quickly
  • Minor delays compound when dependencies cross countries and vendors
4 / 39
WEBINARThe Real Challenges of Global Clinical Research
Table 1Common hidden assumptions in cross-border planning
AssumptionWhat it missesLikely consequence
One protocol fits allCare pathways differDeviations, visit strain
Fast country means fast studyStartup bottlenecks varyLate activation
Big patient pool equals accrualPatients cluster by centerEnrollment lag
English master docs are enoughLocal ICF norms varyRework after sign-off
Central vendors standardize qualityLocal logistics still differWindow misses, queries

Use this as an early challenge checklist during footprint and protocol review.

5 / 39
WEBINARThe Real Challenges of Global Clinical Research
Figure 1How late surprises become timeline loss
flowchart TD
 A[Protocol finalized] --> B[Country startup begins]
 B --> C[Local requirements surface]
 C --> D[Docs and contracts reworked]
 D --> E[Site activation delayed]
 E --> F[Enrollment plan slips]
 F --> G[Resourcing and budget reset]
6 / 39
WEBINARThe Real Challenges of Global Clinical Research

The oncology example shows how local friction hides behind global confidence

In the Phase III oncology study opened across 14 countries, the protocol looked stable and the footprint looked ambitious in all the right ways. Then country-specific ICF language and insurance clauses surfaced after final protocol sign-off, creating five months of preventable delay.

  • The study did not fail scientifically, it failed in startup logic
  • Late ICF and insurance findings forced country-specific rework
  • The critical path changed after teams thought decisions were closed
  • The lesson is simple, local review must happen before final lock
7 / 39
WEBINARThe Real Challenges of Global Clinical Research

Regulatory approval targets may align, but startup routes rarely do

Across major regions, sponsors may be pursuing the same broad approval to run a study, yet the path there differs in timing, document granularity, and local interpretation. That means startup planning must be built around sequence and dependency, not around an average timeline.

  • Authority and ethics steps may run in parallel or in sequence
  • Country packages often need local forms beyond the core dossier
  • Translation expectations differ by document and by reviewer
  • The longest path is often created by local interpretation, not law
8 / 39
WEBINARThe Real Challenges of Global Clinical Research
Table 2Regional startup divergence that changes planning
DimensionCommon variationPlanning effect
Authority timingParallel vs sequentialDifferent critical path
Ethics structureCentral vs local ECsSite package variation
Language needsFull vs partial translationLonger prep cycles
Insurance wordingCountry-specific clausesLegal rework
Import permitsDrug or sample controlsDelayed first patient

Exact rules vary by country, but these patterns are stable enough to plan for.

9 / 39
WEBINARThe Real Challenges of Global Clinical Research

Ethics committee and authority sequencing can reorder the whole startup map

Teams often ask how long approval takes, when the better question is what has to happen before what. If one country allows parallel authority and ethics review while another requires authority feedback before ethics submission, the startup clock is fundamentally different.

  • Sequence changes document readiness and local site engagement
  • Parallel review can save time, if packages are truly complete
  • Sequential review magnifies every missing clause or translation gap
  • Milestones should be country-specific, not globally averaged
10 / 39
WEBINARThe Real Challenges of Global Clinical Research
Figure 2Two startup paths that look similar but behave differently
flowchart LR
 A[Core dossier ready] --> B1[Country A: authority + ethics in parallel]
 A --> B2[Country B: authority first]
 B1 --> C1[Site activation prep]
 B2 --> C2[Ethics submission after authority feedback]
 C1 --> D[First patient in]
 C2 --> D
11 / 39
WEBINARThe Real Challenges of Global Clinical Research

Country-specific documents are not a paperwork nuisance, they are design inputs

Local expectations around informed consent language, indemnity wording, privacy notices, recruitment materials, and import documentation can force changes that affect training, timing, and patient communication. Treating these as late administrative tasks is one of the most expensive habits in global study startup.

  • ICF language often reflects legal and cultural norms, not translation only
  • Insurance and indemnity clauses can trigger sponsor legal review
  • Recruitment materials may need local ethics framing and format
  • Import and export papers connect startup to supply and lab plans
12 / 39
WEBINARThe Real Challenges of Global Clinical Research

Startup governance should track the critical path country by country

A practical startup plan identifies each country's rate-limiting step, the owner, the dependency, and the trigger for escalation. This is less glamorous than talking about global footprint strategy, but it is what keeps optimistic launch plans from collapsing under uneven local readiness.

  • Map one rate-limiting step per country at minimum
  • Separate legal, ethics, authority, and logistics dependencies
  • Escalate by aging assumptions, not by missed milestones alone
  • Use local intelligence before final country commitments
13 / 39
WEBINARThe Real Challenges of Global Clinical Research
Table 3Protocol choices that create uneven burden globally
Design choiceWhy it strains sitesLikely outcome
Dense visit scheduleTravel and staffing pressureMissed windows
Extra exploratory testsLimited local capacityProcedure gaps
Complex eligibilityChart review burdenScreen failure rise
Frequent diary entriesDevice and training needsDropout or missing data
Many exceptionsInterpretation variesDeviation growth

What looks precise in design often becomes fragile in execution.

14 / 39
WEBINARThe Real Challenges of Global Clinical Research

Every extra endpoint and procedure multiplies burden unevenly

Protocol complexity is not neutral. The same schedule that feels manageable in one healthcare setting can become highly disruptive in another where standard of care differs, transport is harder, specialists are scarce, or site staff are shared across many studies.

  • A scientifically elegant protocol can still be operationally brittle
  • Burden is shaped by local care pathways, not protocol intent
  • Uneven burden creates uneven data quality and retention risk
  • Complexity should be tested against country realities before lock
15 / 39
WEBINARThe Real Challenges of Global Clinical Research
Figure 3How one protocol choice expands into downstream operational risk
flowchart TD
 A[Add procedure or endpoint] --> B[Longer visits and more training]
 B --> C[Site workflow strain]
 C --> D[Patient burden increases]
 D --> E[Deviations and missed windows]
 E --> F[Queries, amendments, dropout]
16 / 39
WEBINARThe Real Challenges of Global Clinical Research

Misalignment with local standard of care is a quiet source of protocol failure

Procedures that are routine in one region may be unusual, poorly reimbursed, unavailable, or culturally unfamiliar elsewhere. When protocol activities sit too far outside local practice, sites improvise, patients hesitate, and data consistency starts to fracture.

  • Required tests may depend on referral networks that vary sharply
  • Visit timing may clash with clinic flow and patient travel patterns
  • Procedure expectations can exceed what local staff can support
  • Workarounds tend to surface later as deviations and training issues
17 / 39
WEBINARThe Real Challenges of Global Clinical Research

Translation and consent demands expand with every layer of complexity

A complex protocol requires more explanation, more nuanced consent language, and more training support. That increases the chance that translation choices, literacy gaps, or long consent sessions distort understanding and undermine both enrollment and compliance.

  • Longer ICFs raise comprehension and review burdens
  • Conceptual translation is harder than literal translation
  • Optional substudies often create avoidable consent complexity
  • Complex consent can slow startup and weaken patient confidence
18 / 39
WEBINARThe Real Challenges of Global Clinical Research
Table 4The digital diary example shows complexity is context dependent
ContextUS sitesLower-support sites
Device familiarityOften highMore variable
Training bandwidthBroader support teamsLimited coordinator time
Connectivity accessUsually stablePatchy in some areas
Patient burden effectBetter completionHigher dropout risk
Net resultCleaner daily dataOperational strain

Based on the global CNS trial example where digital diaries helped some regions and hurt others.

19 / 39
WEBINARThe Real Challenges of Global Clinical Research

Patient pools are routinely overestimated because availability is not accessibility

Global feasibility often starts with disease prevalence and investigator optimism. Neither tells you how many diagnosed, eligible, consent-ready patients are actually reachable through local referral pathways and willing to absorb the study burden.

  • Diagnosed patients may be concentrated in a few referral centers
  • Eligibility criteria can erase much of the apparent pool
  • Competing studies and treatment access alter willingness to enroll
  • Forecasts fail when they ignore the path from diagnosis to site
20 / 39
WEBINARThe Real Challenges of Global Clinical Research
Figure 4From prevalence to actual enrollment
flowchart TD
 A[Country prevalence] --> B[Diagnosed patients]
 B --> C[Referred to study-capable centers]
 C --> D[Meet eligibility]
 D --> E[Consent and logistics work]
 E --> F[Randomized patients]
21 / 39
WEBINARThe Real Challenges of Global Clinical Research

The rare disease example warns against trusting feasibility at face value

In the mid-sized CRO rare disease trial spanning Eastern Europe and Latin America, feasibility forecasts looked strong. Actual enrollment lagged because diagnosed patients were concentrated in a few referral centers, and those centers were already managing competing demands and uneven travel access.

  • Country-level prevalence hid referral concentration at center level
  • Strong investigator interest did not equal recruitable throughput
  • Travel and diagnosis pathways limited practical access to sites
  • The fix would have been deeper referral mapping before selection
22 / 39
WEBINARThe Real Challenges of Global Clinical Research

Trust, language, and caregiver burden shape recruitment more than enthusiasm does

Patients do not enroll into a protocol. They enroll into a local experience of trust, explanation, inconvenience, and perceived benefit. Cultural fluency, language support, reimbursement clarity, and caregiver demands often determine whether interest converts into participation.

  • Language support must cover discussion, not just written consent
  • Caregivers often carry hidden scheduling and travel burden
  • Reimbursement confusion can feel like disrespect or risk
  • Local trust in research institutions varies by history and context
23 / 39
WEBINARThe Real Challenges of Global Clinical Research
Table 5Retention risks differ by local context
Risk factorHow it appearsLikely signal
Travel burdenLong distance to visitsLate or missed visits
Caregiver loadWork or family strainWithdrawal requests
Device burdenDiary or app fatigueDeclining completion
Reimbursement delayOut-of-pocket pressureVisit cancellations
Care transitionsCompeting treatment needsProtocol discontinuation

Retention planning should be country- and site-specific, not copied from startup assumptions.

24 / 39
WEBINARThe Real Challenges of Global Clinical Research

Retention fails when sponsors design for enrollment and forget lived follow-through

A patient can fully understand and support the study and still leave because the practical burden becomes unsustainable. Retention planning should start at protocol design and continue through site workflow, communication cadence, transport support, and reimbursement reliability.

  • Ask what will make month four harder than day one
  • Monitor missed visits as burden signals, not just compliance events
  • Support should fit local realities, including caregiver needs
  • Retention risk belongs in operational reviews, not only patient materials
25 / 39
WEBINARThe Real Challenges of Global Clinical Research

Site performance depends on capacity and workflow, not reputation alone

A well-known principal investigator can open doors, but studies are delivered by coordinators, sub-investigators, pharmacists, lab staff, data teams, and finance processes. A site that looks excellent on paper may still underperform if the workload design assumes more bandwidth than the site actually has.

  • Investigator prestige can mask coordinator overload
  • Competing studies dilute attention and screen follow-up
  • Workflow fit matters more than enthusiasm in feasibility calls
  • Real capacity sits below the headline CV
26 / 39
WEBINARThe Real Challenges of Global Clinical Research
Figure 5What site feasibility should really test
flowchart TD
 A[Feasibility questionnaire] --> B[Optimistic capacity estimate]
 B --> C[Startup and training begin]
 C --> D[Competing studies and turnover surface]
 D --> E[Coordinator workload spikes]
 E --> F[Enrollment slows and data lags]
27 / 39
WEBINARThe Real Challenges of Global Clinical Research

Staff turnover and training drift quietly erode consistency

Global studies often run long enough that original training assumptions expire. Coordinators leave, responsibilities shift, local practices evolve, and replacement staff inherit complex workflows through compressed handoffs. The result is often inconsistency that gets misread as site noncompliance.

  • Initial investigator meetings do not protect long study timelines
  • Replacement staff may miss rationale behind key procedures
  • Training records can look complete while understanding is uneven
  • Refresher cadence should follow risk, burden, and turnover patterns
28 / 39
WEBINARThe Real Challenges of Global Clinical Research

Contracting and payment friction directly affect site behavior

Sites notice when contracts stall, budgets miss local realities, and payments arrive late. That friction changes morale, staffing allocation, and willingness to prioritize screening, follow-up, and query response, especially in competitive research environments.

  • Budget assumptions often ignore local pass-through costs
  • Late payments can shift coordinator time to better-funded studies
  • Contract language may trigger long institutional review cycles
  • Operational trust is built through reliable financial mechanics
29 / 39
WEBINARThe Real Challenges of Global Clinical Research
Table 6Source and workflow burdens that predict site underperformance
SignalWhat it often meansPractical response
Slow source entryCoordinator overloadReduce lag, add support
Late query closureCompeting prioritiesTargeted follow-up
Missed visit prepWorkflow mismatchReset task timing
High screening dropEligibility burdenRefine pre-screening
Frequent staff changesTraining driftRefresh role-based training

These are leading indicators, not reasons to blame sites.

30 / 39
WEBINARThe Real Challenges of Global Clinical Research

Data quality problems usually begin as operational mismatches

When teams talk about poor data quality, they often jump straight to monitoring findings or site performance. In global trials, the root cause is frequently earlier and more mundane, such as incompatible systems, local timing variation, weak handoffs, or unclear training on how work should happen.

  • EDC quality reflects workflow design as much as user behavior
  • Local source practices shape what can be entered and when
  • Vendor handoffs create timing gaps that look like site error
  • Queries often reveal process weakness before they reveal misconduct
31 / 39
WEBINARThe Real Challenges of Global Clinical Research
Figure 6How operational mismatch becomes a data issue
flowchart TD
 A[Local practice or tool mismatch] --> B[Delayed or incomplete source flow]
 B --> C[Late EDC entry or inconsistency]
 C --> D[Query volume rises]
 D --> E[Site time diverted to cleanup]
 E --> F[Further lag and frustration]
32 / 39
WEBINARThe Real Challenges of Global Clinical Research

Labs, imaging, and external vendors create hidden cross-border variability

A vendor may be globally contracted yet locally inconsistent in performance because sample routes, customs handling, imaging standards, and service escalation differ by country. The APAC study with acceptable paper turnaround but customs delays for biological samples is a classic example.

  • Central lab KPIs can hide country-level transport bottlenecks
  • Customs delays can push visits outside protocol windows
  • Imaging quality depends on local equipment and reading workflows
  • Vendor oversight should test real path performance, not contract terms
33 / 39
WEBINARThe Real Challenges of Global Clinical Research

The APAC sample-delay example shows why timing assumptions need field testing

In the APAC multi-country study, central lab turnaround looked acceptable in planning documents. But customs delays for biological samples repeatedly pushed visits outside protocol windows, turning a logistics issue into a protocol and data quality issue.

  • The problem was not lab science, it was border movement
  • On-paper turnaround omitted shipping and customs variability
  • Visit window misses created avoidable protocol pressure on sites
  • Early pilot shipments could have exposed the real constraint
34 / 39
WEBINARThe Real Challenges of Global Clinical Research
Table 7A risk-first operating model for global coordination
Risk areaEarly checkpointOwner
Country startupLocal doc and sequence reviewRegulatory lead
Protocol burdenVisit and SOC stress testClinical operations
Recruitment realismReferral pathway validationMedical + country team
Site capacityWorkflow and payment reviewSite management
Data flowVendor and source timing testData operations

Simple ownership beats broad awareness with no decision rights.

35 / 39
WEBINARThe Real Challenges of Global Clinical Research

Resilient programs make tradeoffs explicit before they become expensive facts

A risk-first playbook does not try to remove all uncertainty. It forces teams to name assumptions, decide what evidence would disprove them, assign owners, and review them early enough to change course without drama.

  • List assumptions that matter more than assumptions that are easy
  • Define evidence thresholds for challenge and escalation
  • Assign one owner for each cross-functional risk decision
  • Review assumptions before country expansion is locked
36 / 39
WEBINARThe Real Challenges of Global Clinical Research
Figure 7A simple decision loop for global risk governance
flowchart LR
 A[Name key assumption] --> B[Test with local evidence]
 B --> C[Assign owner and threshold]
 C --> D[Monitor early signal]
 D --> E{Signal holds?}
 E -->|Yes| F[Proceed]
 E -->|No| G[Adapt plan or scope]
37 / 39
WEBINARThe Real Challenges of Global Clinical Research

Use country and site selection guardrails that go beyond speed and cost

Selection decisions should reflect recruitable patients, startup path reliability, site capacity, sample logistics, payment feasibility, and patient burden fit. Countries and sites that look slower or pricier on a summary slide may still produce a more stable study if their assumptions are testable and their operations are durable.

  • Weight reliability and fit alongside speed and budget
  • Challenge prevalence claims with referral-center evidence
  • Screen sites for coordinator load and payment practicality
  • Prefer transparent constraints over optimistic ambiguity
38 / 39
WEBINARThe Real Challenges of Global Clinical Research
Thanks for watching

Run one active study through this risk lens in the next two weeks

  • Choose one active protocol, not a hypothetical future study
  • Invite regulatory, operations, medical, data, and country voices
  • Write down the top three global assumptions at risk
  • Set one follow-up date to confirm actions and ownership
39 / 39